Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/21128
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorMIOSSI, Renata-
dc.contributor.authorSOUZA, Fernando Henrique Carlos de-
dc.contributor.authorSHINJO, Samuel Katsuyuki-
dc.date.accessioned2017-08-01T15:16:01Z-
dc.date.available2017-08-01T15:16:01Z-
dc.date.issued2017-
dc.identifier.citationMEDICALEXPRESS, v.4, n.2, 2017-
dc.identifier.issn2358-0429-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/21128-
dc.description.abstractOBJECTIVES: To evaluate serum levels of C-reactive protein and erythrocyte sedimentation rates in patients with untreated newly diagnosed dermatomyositis or polymyositis and their correlation with clinical and laboratory parameters. METHODS: A cross-sectional study including 48 consecutive patients with untreated newly diagnosed dermatomyositis and polymyositis reviewed between 2002 and 2015 was conducted. Fifty healthy subjects were enrolled as controls. RESULTS: Patients with dermatomyositis and polymyositis had higher levels of C-reactive protein and erythrocyte sedimentation rate than healthy controls, but these values were not associated with clinical or laboratory parameters of disease activity either for dermatomyositis or for polymyositis. Additionally, erythrocyte sedimentation rate values correlated with pulmonary involvement as evidenced through computer tomography imaging (OR 1.15; 95%CI 1.01-1.31) only in patients with polymyositis. CONCLUSIONS: Although elevated, C-reactive protein and erythrocyte sedimentation rate are not sensitive parameters for measuring clinical and laboratory activity of dermatomyositis nor for polymiositis. However, erythrocyte sedimentation rate may be a valid parameter for screening pulmonary involvement, particularly in patients with polymyositis.-
dc.description.abstractOBJETIVOS: Avaliar os níveis séricos da proteína C reativa (PCR) e da velocidade de hemossedimentação (VHS) em pacientes recém-diagnosticados com dermatomiosite (DM) e polimiosite (PM), sem tratamento prévio, correlacionando-os com parâmetros clínico-laboratoriais. MÉTODOS: Estudo transversal que incluiu 48 pacientes consecutivos com DM e PM (critérios de Bohan e Peter) recém-diagnosticados, sem tratamento medicamentoso, no período de 2002 a 2015. Foram incluídos 50 indivíduos saudáveis como grupo controle. RESULTADOS: Os pacientes apresentaram níveis mais elevados de VHS e PCR comparativamente aos controles saudáveis. Estes valores, porém, não se correlacionaram com os parâmetros clínicos e laboratoriais da atividade da doença (DM e PM). Somente em pacientes com PM a VHS apresentou relação com acometimento pulmonar na tomografia computadorizada [OR 1,15 (IC 95% 1,01-1,31)]. CONCLUSÕES: Apesar de aumentadas, a PCR e a VHS não são parâmetros sensíveis para a mensuração da atividade clínica e laboratorial de DM e PM., No entanto, a VHS pode ter validade no rastreio do acometimento pulmonar, particularmente em pacientes com PM.-
dc.language.isoeng-
dc.publisherMavera Edições Técnicas e Científicas Ltda-
dc.relation.ispartofMedicalExpress-
dc.rightsopenAccess-
dc.subjectDermatomyositis-
dc.subjectpolymyositis-
dc.subjectC-reactive protein-
dc.subjecterythrocyte sedimentation rate-
dc.subjectDermatomiosite-
dc.subjectpolimiosite-
dc.subjectproteína C reativa-
dc.subjectvelocidade de hemossedimentação-
dc.titleCould C-reactive protein and erythrocyte sedimentation rate support monitoring of dermatomyositis and polymyositis activity?-
dc.title.alternativeÉ POSSÍVEL SUPOR QUE A PROTEÍNA C REATIVA E A HEMOSSEDIMENTAÇÃO POSSAM SER USADAS PARA MONITORAR A ATIVIDADE DA DERMATOMIOSITE E DA POLIMIOSITE?-
dc.typearticle-
dc.rights.holderCopyright Mavera Edições Técnicas e Científicas Ltda-
dc.identifier.doi10.5935/medicalexpress.2017.02.05-
dc.subject.wosHealth Care Sciences & Services-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.description.issue2-
hcfmusp.description.volume4-
hcfmusp.origemsciELO-
hcfmusp.origem.idSCIELO:S2358-04292017000200004-
hcfmusp.relation.referenceAmerio P, 2002, EUR J DERMATOL, V12, P165-
hcfmusp.relation.referenceBASSETSEGUIN N, 1990, ARCH DERMATOL, V126, P633, DOI 10.1001/archderm.126.5.633-
hcfmusp.relation.referenceBohan A, 1975, N Engl J Med, V292, P344-
hcfmusp.relation.referenceBriani C, 2006, AUTOIMMUNITY, V39, P161, DOI 10.1080/08916930600622132-
hcfmusp.relation.referenceBrigden ML, 1999, AM FAM PHYSICIAN, V60, P1443-
hcfmusp.relation.referenceBurnouf M, 2003, ANN DERMATOL VENER, V130, P313-
hcfmusp.relation.referenceChen D, 2014, CLIN EXP RHEUMATOL, V32, P615-
hcfmusp.relation.referenceDalakas MC, 2011, NEUROPATH APPL NEURO, V37, P226, DOI 10.1111/j.1365-2990.2010.01153.x-
hcfmusp.relation.referenceDalakas MC, 2015, NEW ENGL J MED, V373, P393, DOI 10.1056/NEJMc1506827-
hcfmusp.relation.referenceDalakas MC, 2015, NEW ENGL J MED, V372, P1734, DOI 10.1056/NEJMra1402225-
hcfmusp.relation.referenceDi Rollo D, 2014, GIORN ITAL DERMAT V, V149, P525-
hcfmusp.relation.referenceDiaz MTM, 2017, J Bras Patol Med Lab-
hcfmusp.relation.referenceGABAY C, 1994, ARTHRITIS RHEUM, V37, P1744, DOI 10.1002/art.1780371206-
hcfmusp.relation.referenceGo DJ, 2016, J KOREAN MED SCI, V31, P389, DOI [10.3346/jkms.2016.31.3.389, 10.3346/jkms.2016.31.3.339]-
hcfmusp.relation.referenceIdeura G, 2007, RESP MED, V101, P1406, DOI 10.1016/j.rmed.2007.01.023-
hcfmusp.relation.reference[林辉 Lin Hui], 2013, [四川大学学报. 医学版, Journal of Sichuan University. Medical Science Edition], V44, P805-
hcfmusp.relation.referenceMALLYA RK, 1982, J RHEUMATOL, V9, P224-
hcfmusp.relation.referenceMarie I, 2002, ARTHRIT RHEUM-ARTHR, V47, P614, DOI 10.1002/art.10794-
hcfmusp.relation.referencePark JK, 2013, RHEUMATOLOGY, V52, P1336, DOI 10.1093/rheumatology/ket162-
hcfmusp.relation.referenceCruellas Marcela Gran Pina, 2013, Clinics, V68, P909, DOI 10.6061/clinics/2013(07)04-
hcfmusp.relation.referencePinhata MM, 2015, CLIN EXP RHEUMATOL, V33, P310-
hcfmusp.relation.referenceRider LG, 2004, ARTHRITIS RHEUM, V50, P2281, DOI 10.1002/art.20349-
hcfmusp.relation.referenceRider Lisa G., 2003, Journal of Rheumatology, V30, P603-
hcfmusp.relation.referenceShinjo SK, 2015, CLIN EXP RHEUMATOL, V33, P336-
hcfmusp.relation.referenceSouza Fernando Henrique Carlos de, 2011, Rev Bras Reumatol, V51, P428-
hcfmusp.relation.referenceSouza FH, 2012, Rev Bras Reumatol, V52, P897-
hcfmusp.relation.referenceSparsa A, 2002, ARCH DERMATOL, V138, P885, DOI 10.1001/archderm.138.7.885-
hcfmusp.relation.referenceSun YC, 2013, RHEUMATOL INT, V33, P1295, DOI 10.1007/s00296-012-2545-7-
hcfmusp.relation.referenceTanaka A, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0547-z-
hcfmusp.relation.referenceYe S, 2007, CLIN RHEUMATOL, V26, P1647, DOI 10.1007/s10067-007-0562-9-
dc.description.indexSciELO-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/17
LIM/17 - Laboratório de Investigação em Reumatologia


Files in This Item:
File Description SizeFormat 
art_MIOSSI_Could_Creactive_protein_and_erythrocyte_sedimentation_rate_support_2017.PDFpublishedVersion (English)285.87 kBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.